We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. markets closed

Protalix BioTherapeutics, Inc. (PLX)

NYSE American - NYSE American Delayed Price. Currency in USD
1.6200-0.0100 (-0.61%)
At close: 04:00PM EST
1.6200 0.00 (0.00%)
After hours: 05:10PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close1.6300
Open1.6800
Bid1.6200 x 900
Ask1.6300 x 1800
Day's Range1.6200 - 1.6800
52 Week Range1.2100 - 3.5500
Volume472,492
Avg. Volume307,753
Market Cap118.182M
Beta (5Y Monthly)0.88
PE Ratio (TTM)18.00
EPS (TTM)0.0900
Earnings DateMay 02, 2024 - May 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
81% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for PLX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Protalix BioTherapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 10/23/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • PR Newswire

    Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference

    Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced that it will attend and present at the 2024 BIO CEO & Investor Conference taking place February 26-27, 2024 at the New York Marriott Marquis in New York City.

  • PR Newswire

    Protalix BioTherapeutics Issues 2024 Letter to Stockholders

    Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its stockholders.

  • GlobeNewswire

    Levicept Appoints Eliot Forster as CEO

    Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty y

  • Insider Monkey

    Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2023 Earnings Call Transcript

    Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2023 Earnings Call Transcript November 6, 2023 Protalix BioTherapeutics, Inc. beats earnings expectations. Reported EPS is $-0.04, expectations were $-0.07. Operator: Good morning, ladies and gentlemen. And welcome to the Protalix Biotherapeutics Third Quarter 2023 Financial and Business Results Conference Call. As a reminder, this conference is being recorded. I […]

  • Zacks Small Cap Research

    PLX: More Regulatory Approvals

    By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Third Quarter 2023 Financial and Operational Review Protalix Biotherapeutics, Inc. (NYSE:PLX) announced 3Q:23 financial and operational results in a November 6th, 2023 press release and filing of Form 10-Q . The reports were followed by a conference call which discussed recent achievements, regulatory updates and financial

  • GuruFocus.com

    Protalix BioTherapeutics Inc (PLX) Reports Q3 2023 Financial Results

    Protalix BioTherapeutics Inc (PLX) reported a net income of $14.36 million for Q3 2023, a significant improvement from a loss of $11.19 million in the same period last year. The company's cash and cash equivalents increased to $20.41 million from $17.11 million at the end of 2022. Protalix continues to advance its clinical trial of PRX-115, a potential treatment for severe gout, with top-line results expected in mid-2024.

  • PR Newswire

    Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results

    Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the third quarter ended September 30, 2023 and provided a business update on recent regulatory, clinical and corporate developments.

  • PR Newswire

    Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023

    Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will release its financial results for the third quarter ended September 30, 2023 and provide a business update on Monday, November 6, 2023.

  • PR Newswire

    Protalix BioTherapeutics Issues Statement Regarding Security Situation in Israel

    Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today issued the following statement by Dror Bashan, Protalix's President and Chief Executive Officer, regarding the current security situation in Israel.

  • PR Newswire

    Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

    Appointment effective as of September 14, 2023;Zeev Bronfeld to retire from the Board of Directors